← Back to Patent Explorer
US4039669A Expired / Lapsed US ⏱️ 0.0 years remaining

Composition for topical application and use thereof

Assignee: STWB Inc
•
Filing: 1975-08-01
•
Granted: 1977-08-02
•
Expires: 1995-08-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A composition for topical treatment of dermatological conditions associated with androgenic stimulatory influences, e.g. acne, which comprises 17α-R-androst-4-en-17β-ol-3-one or an ester thereof in an appropriate pharmaceutical formulation; and a method of treating such dermatological conditions therewith.

Inventors

  • 👤 Arthur L. Beyler
  • 👤 Richard A. Ferrari

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 13:21
CPC Classifications
C; C07; C07J; C07J1/00; C07J1/0003; C07J1/0033; C07J1/0037; A; A61; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/63; A61Q; A61Q19/00; A61Q7/00

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 41 words
A composition for topical treatment of dermatological conditions associated with androgenic stimulatory influences which comprises an anti-androgenically effective amount of 17α-R-androst-4-en-17β-ol-3-one or a pharmaceutically acceptable ester thereof, where R is n-propyl or n-butyl, in a pharmaceutical formulation suitable for topical application.
Claim 2
Dependent Claim 41 words
A composition for topical treatment of dermatological conditions associated with androgenic stimulatory influences which comprises an anti-androgenically effective amount of 17α-R-androst-4-en-17β-ol-3-one or a pharmaceutically acceptable ester thereof, where R is n-propyl or n-butyl, in a pharmaceutical formulation suitable for topical application.
Claim 3
Dependent Claim 24 words
A composition according to claim 1 in which the anti-androgenically effective compound is 17α-(n-propyl)androst-4-en-17β-ol-3-one in a concentration of 0.1 to 5.0 percent by weight.
Claim 4
Dependent Claim 24 words
A composition according to claim 1 in which the anti-androgenically effective compound is 17α-(n-butyl)androst-4-en-17β-ol-3-one in a concentration of 0.1 to 5.0 percent by weight.
Claim 5
Dependent Claim 25 words
A method of treating dermatological conditions associated with androgenic stimulatory influences which comprises applying to the affected skin area a composition according to claim 1.
Claim 6
Dependent Claim 25 words
A method of treating dermatological conditions associated with androgenic stimulatory influences which comprises applying to the affected skin area a composition according to claim 2.
Claim 7
Dependent Claim 25 words
A method of treating dermatological conditions associated with androgenic stimulatory influences which comprises applying to the affected skin area a composition according to claim 3.

References Cited (Backward Citations)

US2855341A Cited
GB854407A Cited
GB846920A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-08-01 1981-01-31 1981-08-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-08-01 1985-01-31 1985-08-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-08-01 1989-01-31 1989-08-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag